NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced manufacturing, research and ...

Johnson & Johnson (NYSE:JNJ) announced today that it received FDA de novo authorization for its Ottava surgical robot system.

JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies ...

Johnson & Johnson JNJ on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full ...

Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ ...

The drug and medical-device maker raised its forecast for the year after recording higher sales in the second quarter.

Johnson & Johnson offers a combination of an AAA-tier balance sheet, a 64-consecutive year dividend growth streak and a ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

For 2026, Johnson & Johnson anticipates operational sales growth in the range of 5.7% to 6.7% with a midpoint of $100 billion or 6.2%. Reported sales growth is expected between 6.2% to 7.2% with a ...

When most people experience an itch, they think nothing of it; a simple scratch can usually tame it. The itch experienced by people living with atopic dermatitis (AD), commonly known as eczema, is ...

If health care industry corruption and criminality were a city skyline, it would be booming, with tower cranes and half-built skyscrapers in every direction. Among the downtown giants at the center ...